Biokin’s Iza-Bren Scores Second Phase III OS Win In China Trial

But Trial Excluded Certain Previous Treatments

 
• By Dexter Jie Yan
  
Iza-bren significantly extended the OS and PFS against chemotherapies in a China-only Phase III trial in second and later-line triple-negative breast cancer. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D